1. Adli, M., The CRISPR tool kit for genome editing and beyond. Nature communications, 2018. 9(1): p. 1-13.
2. Rothstein, R.J., [12] One-step gene disruption in yeast. Methods in enzymology, 1983. 101: p. 202-211.
3. Capecchi, M.R., Altering the genome by homologous recombination. Science, 1989. 244(4910): p. 1288-1292.
4. Lin, F., K. Sperle, and N. Sternberg, Recombination in mouse L cells between DNA introduced into cells and homologous chromosomal sequences. Proceedings of the National Academy of Sciences, 1985. 82(5): p. 1391-1395.
5. Rudin, N., E. Sugarman, and J.E. Haber, Genetic and physical analysis of double-strand break repair and recombination in Saccharomyces cerevisiae. Genetics, 1989. 122(3): p. 519-534.
6. Rouet, P., F. Smih, and M. Jasin, Introduction of double-strand breaks into the genome of mouse cells by expression of a rare-cutting endonuclease. Molecular and cellular biology, 1994. 14(12): p. 8096-8106.
7. Jeggo, P., 5 DNA Breakage and Repair, in Advances in genetics. 1998, Elsevier. p. 185-218.
8. Klug, A. and D. Rhodes. Zinc fingers: a novel protein fold for nucleic acid recognition. in Cold Spring Harbor symposia on quantitative biology. 1987. Cold Spring Harbor Laboratory Press.
9. Kim, Y.-G., J. Cha, and S. Chandrasegaran, Hybrid restriction enzymes: zinc finger fusions to Fok I cleavage domain. Proceedings of the National Academy of Sciences, 1996. 93(3): p. 1156-1160.

10.Bibikova, M., et al., Stimulation of homologous recombination through targeted cleavage by chimeric nucleases. Molecular and cellular biology, 2001. 21(1): p. 289-297.

11.Porteus, M.H. and D. Baltimore, Chimeric nucleases stimulate gene targeting in human cells. Science, 2003. 300(5620): p. 763-763.

12.Boch, J., et al., Breaking the code of DNA binding specificity of TAL-type III effectors. Science, 2009. 326(5959): p. 1509-1512.

13.Moscou, M.J. and A.J. Bogdanove, A simple cipher governs DNA recognition by TAL effectors. Science, 2009. 326(5959): p. 1501-1501.

14.Gaj, T., C.A. Gersbach, and C.F. Barbas III, ZFN, TALEN, and CRISPR/Cas-based methods for genome engineering. Trends in biotechnology, 2013. 31(7): p. 397-405.

15.Jansen, R., et al., Identification of genes that are associated with DNA repeats in prokaryotes. Molecular microbiology, 2002. 43(6): p. 1565-1575.

16.Ishino, Y., et al., Nucleotide sequence of the iap gene, responsible for alkaline phosphatase isozyme conversion in Escherichia coli, and identification of the gene product. Journal of bacteriology, 1987. 169(12): p. 5429-5433.

17.Mojica, F.J., et al., Biological significance of a family of regularly spaced repeats in the genomes of Archaea, Bacteria and mitochondria. Molecular microbiology, 2000. 36(1): p. 244-246.

18.Maeder, M.L., et al., CRISPR RNA–guided activation of endogenous human genes. Nature methods, 2013. 10(10): p. 977-979.

19.Barrangou, R., et al., CRISPR provides acquired resistance against viruses in prokaryotes. Science, 2007. 315(5819): p. 1709-1712.

20.Marraffini, L.A. and E.J. Sontheimer, Self versus non-self discrimination during CRISPR RNA-directed immunity. Nature, 2010. 463(7280): p. 568-571.

21.Brouns, S.J., et al., Small CRISPR RNAs guide antiviral defense in prokaryotes. Science, 2008. 321(5891): p. 960-964.

22.Marraffini, L.A. and E.J. Sontheimer, CRISPR interference limits horizontal gene transfer in staphylococci by targeting DNA. science, 2008. 322(5909): p. 1843-1845.

23.Haft, D.H., et al., A guild of 45 CRISPR-associated (Cas) protein families and multiple CRISPR/Cas subtypes exist in prokaryotic genomes. PLoS computational biology, 2005. 1(6).

24.Makarova, K.S., et al., Evolution and classification of the CRISPR–Cas systems. Nature Reviews Microbiology, 2011. 9(6): p. 467-477.

25.Khan, S., et al., CRISPR/Cas9: the Jedi against the dark empire of diseases. Journal of biomedical science, 2018. 25(1): p. 29.

26.Abudayyeh, O.O., et al., C2c2 is a single-component programmable RNA-guided RNA-targeting CRISPR effector. Science, 2016. 353(6299): p. aaf5573.

27.Deveau, H., et al., Phage response to CRISPR-encoded resistance in Streptococcus thermophilus. Journal of bacteriology, 2008. 190(4): p. 1390-1400.

28.Zetsche, B., et al., Cpf1 is a single RNA-guided endonuclease of a class 2 CRISPR-Cas system. Cell, 2015. 163(3): p. 759-771.

29.Garneau, J.E., et al., The CRISPR/Cas bacterial immune system cleaves bacteriophage and plasmid DNA. Nature, 2010. 468(7320): p. 67-71.

30.Deltcheva, E., et al., CRISPR RNA maturation by trans-encoded small RNA and host factor RNase III. Nature, 2011. 471(7340): p. 602-607.

31.Sapranauskas, R., et al., The Streptococcus thermophilus CRISPR/Cas system provides immunity in Escherichia coli. Nucleic acids research, 2011. 39(21): p. 9275-9282.

32.Jinek, M., et al., A programmable dual-RNA–guided DNA endonuclease in adaptive bacterial immunity. science, 2012. 337(6096): p. 816-821.

33.Gasiunas, G., et al., Cas9–crRNA ribonucleoprotein complex mediates specific DNA cleavage for adaptive immunity in bacteria. Proceedings of the National Academy of Sciences, 2012. 109(39): p. E2579-E2586.

34.Wright, W.D., S.S. Shah, and W.-D. Heyer, Homologous recombination and the repair of DNA double-strand breaks. Journal of Biological Chemistry, 2018. 293(27): p. 10524-10535.

35.McVey, M. and S.E. Lee, MMEJ repair of double-strand breaks (director’s cut): deleted sequences and alternative endings. Trends in Genetics, 2008. 24(11): p. 529-538.

36.Zhao, X., et al., Cell cycle-dependent control of homologous recombination. Acta biochimica et biophysica Sinica, 2017. 49(8): p. 655-668.

37.Eid, A., S. Alshareef, and M.M. Mahfouz, CRISPR base editors: genome editing without double-stranded breaks. Biochemical Journal, 2018. 475(11): p. 1955-1964.

38.Komor, A.C., et al., Programmable editing of a target base in genomic DNA without double-stranded DNA cleavage. Nature, 2016. 533(7603): p. 420-424.

39.Gaudelli, N.M., et al., Programmable base editing of A• T to G• C in genomic DNA without DNA cleavage. Nature, 2017. 551(7681): p. 464-471.

40.Hou, Z., et al., Efficient genome engineering in human pluripotent stem cells using Cas9 from Neisseria meningitidis. Proceedings of the National Academy of Sciences, 2013. 110(39): p. 15644-15649.

41.Ran, F.A., et al., In vivo genome editing using Staphylococcus aureus Cas9. Nature, 2015. 520(7546): p. 186-191.

42.Friedland, A.E., et al., Characterization of Staphylococcus aureus Cas9: a smaller Cas9 for all-in-one adeno-associated virus delivery and paired nickase applications. Genome biology, 2015. 16(1): p. 257.

43.Kim, E., et al., In vivo genome editing with a small Cas9 orthologue derived from Campylobacter jejuni. Nature communications, 2017. 8: p. 14500.

44.Hirano, H., et al., Structure and engineering of Francisella novicida Cas9. Cell, 2016. 164(5): p. 950-961.

45.Mojica, F.J., J. García-Martínez, and E. Soria, Intervening sequences of regularly spaced prokaryotic repeats derive from foreign genetic elements. Journal of molecular evolution, 2005. 60(2): p. 174-182.

46.Yamano, T., et al., Crystal structure of Cpf1 in complex with guide RNA and target DNA. Cell, 2016. 165(4): p. 949-962.

47.Zuo, E., et al., Cytosine base editor generates substantial off-target single-nucleotide variants in mouse embryos. Science, 2019. 364(6437): p. 289-292.

48.Jin, S., et al., Cytosine, but not adenine, base editors induce genome-wide off-target mutations in rice. Science, 2019. 364(6437): p. 292-295.

49.Ran, F.A., et al., Double nicking by RNA-guided CRISPR Cas9 for enhanced genome editing specificity. Cell, 2013. 154(6): p. 1380-1389.

50.Guilinger, J.P., D.B. Thompson, and D.R. Liu, Fusion of catalytically inactive Cas9 to FokI nuclease improves the specificity of genome modification. Nature biotechnology, 2014. 32(6): p. 577.

51.Tsai, S.Q., et al., Dimeric CRISPR RNA-guided FokI nucleases for highly specific genome editing. Nature biotechnology, 2014. 32(6): p. 569-576.

52.Nishimasu, H., et al., Crystal structure of Cas9 in complex with guide RNA and target DNA. Cell, 2014. 156(5): p. 935-949.

53.Lei, Y., et al., Targeted DNA methylation in vivo using an engineered dCas9-MQ1 fusion protein. Nature communications, 2017. 8(1): p. 1-10.

54.Moon, S.B., J.-H. Ko, and Y.-S. Kim, Recent advances in the CRISPR genome editing tool set. Experimental & molecular medicine, 2019. 51(11): p. 1-11.

55.Qi, L.S., et al., Repurposing CRISPR as an RNA-guided platform for sequence-specific control of gene expression. Cell, 2013. 152(5): p. 1173-1183.

56.Gilbert, L.A., et al., CRISPR-mediated modular RNA-guided regulation of transcription in eukaryotes. Cell, 2013. 154(2): p. 442-451.

57.Urrutia, R., KRAB-containing zinc-finger repressor proteins. Genome biology, 2003. 4(10): p. 231.

58.Konermann, S., et al., Genome-scale transcriptional activation by an engineered CRISPR-Cas9 complex. Nature, 2015. 517(7536): p. 583-588.

59.Friedman, J.R., et al., KAP-1, a novel corepressor for the highly conserved KRAB repression domain. Genes & development, 1996. 10(16): p. 2067-2078.

60.Groner, A.C., et al., KRAB–zinc finger proteins and KAP1 can mediate long-range transcriptional repression through heterochromatin spreading. PLoS genetics, 2010. 6(3).

61.Wysocka, J. and W. Herr, The herpes simplex virus VP16-induced complex: the makings of a regulatory switch. Trends in biochemical sciences, 2003. 28(6): p. 294-304.

62.Cheng, A.W., et al., Multiplexed activation of endogenous genes by CRISPR-on, an RNA-guided transcriptional activator system. Cell research, 2013. 23(10): p. 1163-1171.

63.Chavez, A., et al., Highly efficient Cas9-mediated transcriptional programming. Nature methods, 2015. 12(4): p. 326-328.

64.Hardwick, J.M., et al., The Epstein-Barr virus R transactivator (Rta) contains a complex, potent activation domain with properties different from those of VP16. Journal of virology, 1992. 66(9): p. 5500-5508.

65.Sugiyama, T. and D. Nakada, Translational control of bacteriophage MS2 RNA cistrons by MS2 coat protein: polyacrylamide gel electrophoretic analysis of proteins synthesized in vitro. Journal of molecular biology, 1968. 31(3): p. 431-440.

66.Peabody, D.S., The RNA binding site of bacteriophage MS2 coat protein. The EMBO journal, 1993. 12(2): p. 595-600.

67.Zalatan, J.G., et al., Engineering complex synthetic transcriptional programs with CRISPR RNA scaffolds. Cell, 2015. 160(1-2): p. 339-350.

68.Tanenbaum, M.E., et al., A protein-tagging system for signal amplification in gene expression and fluorescence imaging. Cell, 2014. 159(3): p. 635-646.

69.Chavez, A., et al., Comparison of Cas9 activators in multiple species. Nature methods, 2016. 13(7): p. 563-567.

70.Qu, H. and X. Fang, A brief review on the Human Encyclopedia of DNA Elements (ENCODE) project. Genomics, proteomics & bioinformatics, 2013. 11(3): p. 135-141.

71.Bernstein, B.E., et al., The NIH roadmap epigenomics mapping consortium. Nature biotechnology, 2010. 28(10): p. 1045-1048.

72.Razin, A. and A.D. Riggs, DNA methylation and gene function. Science, 1980. 210(4470): p. 604-610.

73.Okano, M., et al., DNA methyltransferases Dnmt3a and Dnmt3b are essential for de novo methylation and mammalian development. Cell, 1999. 99(3): p. 247-257.

74.Kaminskas, E., et al., FDA Commentary. The oncologist, 2005. 10: p. 176-182.

75.Galonska, C., et al., Genome-wide tracking of dCas9-methyltransferase footprints. Nature communications, 2018. 9(1): p. 1-9.

76.Polstein, L.R. and C.A. Gersbach, A light-inducible CRISPR-Cas9 system for control of endogenous gene activation. Nature chemical biology, 2015. 11(3): p. 198-200.

77.Jensen, E.D., et al., Transcriptional reprogramming in yeast using dCas9 and combinatorial gRNA strategies. Microbial cell factories, 2017. 16(1): p. 46.

78.Nakamura, M., et al., Anti-CRISPR-mediated control of gene editing and synthetic circuits in eukaryotic cells. Nature communications, 2019. 10(1): p. 1-11.

79.Hanewich-Hollatz, M.H., et al., Conditional guide RNAs: Programmable conditional regulation of CRISPR/cas function in bacterial and mammalian cells via dynamic RNA nanotechnology. ACS central science, 2019. 5(7): p. 1241-1249.

80.Braun, S.M., et al., Rapid and reversible epigenome editing by endogenous chromatin regulators. Nature communications, 2017. 8(1): p. 1-8.

81.Klann, T.S., et al., CRISPR–Cas9 epigenome editing enables high-throughput screening for functional regulatory elements in the human genome. Nature biotechnology, 2017. 35(6): p. 561.

82.Chakraborty, S., et al., A CRISPR/Cas9-based system for reprogramming cell lineage specification. Stem cell reports, 2014. 3(6): p. 940-947.

83.Balboa, D., et al., Conditionally stabilized dCas9 activator for controlling gene expression in human cell reprogramming and differentiation. Stem cell reports, 2015. 5(3): p. 448-459.

84.Bialek, J.K., et al., Targeted HIV-1 latency reversal using CRISPR/Cas9-derived transcriptional activator systems. PloS one, 2016. 11(6).

85.Lino, C.A., et al., Delivering CRISPR: a review of the challenges and approaches. Drug delivery, 2018. 25(1): p. 1234-1257.

86.Ibraheim, R., et al., All-in-one adeno-associated virus delivery and genome editing by Neisseria meningitidis Cas9 in vivo. Genome biology, 2018. 19(1): p. 137.

87.Li, A., et al., A self-deleting AAV-CRISPR system for in vivo genome editing. Molecular Therapy-Methods & Clinical Development, 2019. 12: p. 111-122.

88.Karvelis, T., et al., PAM recognition by miniature CRISPR-Cas14 triggers programmable double-stranded DNA cleavage. bioRxiv, 2019: p. 654897.

89.Charlesworth, C.T., et al., Identification of preexisting adaptive immunity to Cas9 proteins in humans. Nature medicine, 2019. 25(2): p. 249-254.

90.Kim, S., et al., CRISPR RNAs trigger innate immune responses in human cells. Genome research, 2018. 28(3): p. 367-373.